Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists
Graphical abstract
This paper describes the preparation, by a novel route, of A2A receptor antagonists containing the [1,2,4]triazolo[1,5-a] pyrazine nucleus, which is isomeric with the [1,2,4]triazolo[1,5-c]pyrimidine core of a series of known A2A antagonists with in vivo activity in animal models of Parkinson’s disease.
References and notes (22)
Drugs Future
(2000)et al.Br. J. Pharmacol.
(1994)- et al.
TIPS
(1997) - et al.
Bioorg. Med. Chem. Lett.
(1997)et al.Curr. Opin. Inv. Drugs
(2001)et al.Ann. Neurol.
(1998)et al.Neurology
(2003) - et al.
Curr. Top. Med. Chem.
(2003) - et al.
Bioorg. Med. Chem. Lett.
(2004) - et al.
J. Med. Chem.
(1992) - et al.
Pharmacol. Rev.
(1994)et al.Pharmacol. Rev.
(1998)et al.Curr. Pharm. Des.
(1996) - et al.
Bioorg. Med. Chem.
(1998) - et al.
J. Neurosci.
(2001)
Cited by (28)
Diversity-oriented synthesis of bicyclic fragments containing privileged azines
2019, Bioorganic and Medicinal Chemistry LettersRegioselectivity in 2-X-pyrazine aminations by O-mesitylenesulfonylhydroxylamine
2009, Tetrahedron LettersSynthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A<inf>2A</inf> receptor antagonists
2008, Bioorganic and Medicinal Chemistry LettersChapter 6.2 (2005) Six-membered ring systems: diazines and benzo derivatives (2005)
2008, Progress in Heterocyclic ChemistryPotent, selective, and orally active adenosine A<inf>2A</inf> receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
2007, Bioorganic and Medicinal Chemistry Letters
Copyright © 2005 Elsevier Ltd. All rights reserved.